Company Profile
Company Profile

ETERN was established in 2018, focusing on the research and development of small molecule drugs targeting protein liquid-liquid phase separation. The LLPS platform, the state-of-art protein liquid-liquid phase separation platform developed by Etern, integrate cutting edge techniques including protein phase separation biology, AI-based target identification and verification, phase separation-based phenotypic screening, image recognition-based hit finding, etc. The platform provides a novel strategy for drug R&D, especially for “undruggable"targets.

2018
Established Time
LLPSPlatform
Focus on liquid-liquid phase separation
Our History
  • 2018
    Established in December
  • 2019
    Angel round financing
  • 2020
    Round A financing
  • 2021
    Round B financing
    1st clinical projrct approved in China and the United States
  • 2022
    Collaborated with Roche Shanghai Innovation Center
    Research published on the cover of “Nature Chemical Biology”
  • 2023
    Research published in “PNAS”
Core Team
ETERN has a R&D team with innovative spirit, rich experience, and efficient collaboration.
Management team
Dr. Jidong ZHU
Co-founder & CEO
Rachel Zhu,
Head of Operations
Scientific Advisors
Prof. Junying YUAN
Member of American Academy of Sciences and American Academy of Arts and Sciences,
Prof. Mingjie ZHANG
Academician of the CAS Member, Structural Biologist